

Relationship between the Serotonergic Activity and Re Amphetamine Analogs

Journal of Pharmacology and Experimental Therapeutics
313, 848-854

DOI: [10.1124/jpet.104.080101](https://doi.org/10.1124/jpet.104.080101)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1361-1369.	1.3	83
2	Role of the increased noradrenergic neurotransmission in drug self-administration. <i>Drug and Alcohol Dependence</i> , 2006, 82, 151-157.	1.6	23
3	Therapeutic Potential of Monoamine Transporter Substrates. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1845-1859.	1.0	53
4	Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 105-112.	4.0	67
5	Dual dopamine/5-HT releasers: potential treatment agents for cocaine addiction. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 612-618.	4.0	39
6	Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment.. <i>Experimental and Clinical Psychopharmacology</i> , 2006, 14, 20-33.	1.3	39
7	Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine-Type Drugs. <i>Annals of the New York Academy of Sciences</i> , 2006, 1074, 245-260.	1.8	108
8	Estimating the relative reinforcing strength of (±)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. <i>Psychopharmacology</i> , 2006, 189, 483-488.	1.5	53
9	Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 84, 337-343.	1.3	47
10	Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 454-463.	1.3	24
11	Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 757-765.	1.3	69
12	Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist" Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 627-636.	1.3	70
14	Serotonin and psychostimulant addiction: Focus on 5-HT _{1A} -receptors. <i>Progress in Neurobiology</i> , 2007, 81, 133-178.	2.8	297
15	The effects of concurrent administration of (±)-3,4-Methylenedioxymethamphetamine and cocaine on conditioned place preference in the adult male rat. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 88, 165-170.	1.3	19
16	Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. <i>AAPS Journal</i> , 2007, 9, E1-E10.	2.2	55
17	MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. <i>European Journal of Neuroscience</i> , 2007, 26, 3229-3236.	1.2	75
18	Serotonin (5-HT) Transporter Ligands Affect Plasma 5-HT in Rats. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 268-284.	1.8	20
19	Monoamine transporters and psychostimulant addiction. <i>Biochemical Pharmacology</i> , 2008, 75, 196-217.	2.0	189

#	ARTICLE	IF	CITATIONS
20	Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 453-462.	1.3	42
21	Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 458-474.	1.3	57
22	Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). <i>British Journal of Pharmacology</i> , 2008, 154, 606-622.	2.7	97
23	Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (<i>1S</i>,<i>2S</i>)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 573-583.	1.3	47
24	Dopamine/serotonin releasers as medications for stimulant addictions. <i>Progress in Brain Research</i> , 2008, 172, 385-406.	0.9	38
26	Nonhuman primate neuroimaging and cocaine medication development.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 446-457.	1.3	10
27	MDMA Self-Administration in Laboratory Animals: A Summary of the Literature and Proposal for Future Research. <i>Neuropsychobiology</i> , 2009, 60, 130-136.	0.9	47
28	Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 272-281.	1.3	34
29	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 236-248.	1.3	14
30	Lack of Cocaine Self-Administration in Mice Expressing a Cocaine-Insensitive Dopamine Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 204-211.	1.3	90
31	Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 94, 278-284.	1.3	18
32	Changes in feeding and locomotion induced by amphetamine analogs in rats. <i>Drug and Alcohol Dependence</i> , 2009, 100, 234-239.	1.6	30
34	Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. <i>Psychopharmacology</i> , 2010, 210, 75-83.	1.5	15
35	In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 218-225.	1.3	95
36	Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. <i>Life Sciences</i> , 2011, 88, 586-589.	2.0	7
37	Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. <i>Behavioural Pharmacology</i> , 2011, 22, 824-836.	0.8	41
39	Dopaminergic mechanisms of reinstatement of MDMA-seeking behaviour in rats. <i>British Journal of Pharmacology</i> , 2011, 162, 1770-1780.	2.7	39
40	MDMA (‘ecstasy’) abuse as an example of dopamine neuroplasticity. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 1203-1218.	2.9	33

#	ARTICLE	IF	CITATIONS
41	Agonist replacement therapy for cocaine dependence: a translational review. <i>Future Medicinal Chemistry</i> , 2012, 4, 245-265.	1.1	44
42	Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. <i>Brain Research</i> , 2012, 1470, 119-129.	1.1	10
43	GC-MS and GC-IRD analysis of 2-, 3- and 4-methylmethamphetamine and 2-, 3- and 4-methylamphetamine. <i>Forensic Science International</i> , 2012, 220, 67-73.	1.3	18
44	Fluorine in psychedelic phenethylamines. <i>Drug Testing and Analysis</i> , 2012, 4, 577-590.	1.6	28
45	Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. <i>Psychopharmacology</i> , 2012, 220, 751-762.	1.5	79
46	Isomers of fluoroamphetamines detected in forensic cases in Denmark. <i>International Journal of Legal Medicine</i> , 2012, 126, 541-547.	1.2	35
47	Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. <i>Forensic Science International</i> , 2012, 215, 3-7.	1.3	24
48	Synthetic Amphetamine Derivatives. , 2013, , 161-178.		6
49	Computer-aided (<i>in silico</i>) approaches in the mode-of-action analysis and safety assessment of Ostarine and 4-methylamphetamine. <i>Human Psychopharmacology</i> , 2013, 28, 365-378.	0.7	2
50	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive "Bath Salts"™ Products. <i>Neuropsychopharmacology</i> , 2013, 38, 552-562.	2.8	361
51	Pharmacological characterization of designer cathinones <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2013, 168, 458-470.	2.7	576
52	Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. <i>British Journal of Pharmacology</i> , 2013, 168, 850-862.	2.7	102
53	The identification of 4-methylamphetamine and its synthesis by-products in forensic samples. <i>Forensic Science International</i> , 2013, 228, 115-131.	1.3	14
54	Differentiation of regioisomeric fluoroamphetamine analogs by gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry. <i>Forensic Toxicology</i> , 2013, 31, 241-250.	1.4	32
55	4-Methyl-amphetamine: a health threat for recreational amphetamine users. <i>Journal of Psychopharmacology</i> , 2013, 27, 817-822.	2.0	34
56	Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1985-1998.	1.0	15
57	Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats. <i>Behavioural Pharmacology</i> , 2013, 24, 448-458.	0.8	13
58	Abuse liability of novel "legal high"™ designer stimulants. <i>Behavioural Pharmacology</i> , 2013, 24, 341-355.	0.8	16

#	ARTICLE	IF	CITATIONS
59	Differentiation of regioisomeric methylamphetamines by GC/MS. Japanese Journal of Forensic Science and Technology, 2014, 19, 111-119.	0.1	5
60	Bath Salts, Mephedrone, and Methylenedioxypropylamphetamine as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention. Advances in Pharmacology, 2014, 69, 581-620.	1.2	64
61	Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse. Advances in Pharmacology, 2014, 69, 129-176.	1.2	50
62	Emerging drugs of abuse: current perspectives on substituted cathinones. Substance Abuse and Rehabilitation, 2014, 5, 37.	1.6	63
63	Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MS n. Analytical and Bioanalytical Chemistry, 2014, 406, 1957-1974.	1.9	30
64	Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochemical Pharmacology, 2014, 88, 237-244.	2.0	85
65	Synthetic Cathinones (‘‘Bath Salts’’). Journal of Emergency Medicine, 2014, 46, 632-642.	0.3	131
66	Pharmacology of novel synthetic stimulants structurally related to the ‘‘bath salts’’ constituent 3,4-methylenedioxypropylamphetamine (MDPV). Neuropharmacology, 2014, 87, 206-213.	2.0	176
67	Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacology, 2014, 87, 66-80.	2.0	28
68	Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release. Addiction Biology, 2014, 19, 874-884.	1.4	45
69	Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, 2014, 79, 152-160.	2.0	176
70	Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs. Pharmacological Reviews, 2014, 66, 869-917.	7.1	185
71	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.. Experimental and Clinical Psychopharmacology, 2014, 22, 274-284.	1.3	16
72	Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (‘‘Ecstasy’’™) Substance Use Disorder. Current Topics in Behavioral Neurosciences, 2015, 34, 17-32.	0.8	2
74	New Synthetic Drugs in Addictovigilance. Therapie, 2015, 70, 179-189.	0.6	10
75	Do the risks of khat-induced dependence and psychosis warrant the 2014 UK ban?. Drug Science, Policy and Law, 2015, 2, 205032451662844.	0.6	1
76	4-Fluoroamphetamine in the Netherlands: more than a one-night stand. Addiction, 2015, 110, 1138-1143.	1.7	42
77	Serotonin 5-HT ₂ Receptor Interactions with Dopamine Function: Implications for Therapeutics in Cocaine Use Disorder. Pharmacological Reviews, 2015, 67, 176-197.	7.1	214

#	ARTICLE	IF	CITATIONS
78	Serotonin is involved in the psychostimulant and hypothermic effect of 4-methylamphetamine in rats. <i>Neuroscience Letters</i> , 2015, 590, 68-73.	1.0	5
79	Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. <i>European Neuropsychopharmacology</i> , 2015, 25, 365-376.	0.3	162
80	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. <i>Drug and Alcohol Dependence</i> , 2015, 147, 1-19.	1.6	116
81	Effects of α -Pyrrolidinopentiophenone and 4-Methyl-N-Ethylcathinone, Two Synthetic Cathinones Commonly Found in Second-Generation "Bath Salts," on Intracranial Self-Stimulation Thresholds in Rats. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu014-pyu014.	1.0	30
82	Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. <i>Pain</i> , 2015, 156, 175-184.	2.0	30
83	In vivo potency and efficacy of the novel cathinone α -pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. <i>Psychopharmacology</i> , 2015, 232, 3045-3055.	1.5	92
84	Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. <i>Swiss Medical Weekly</i> , 2015, 145, w14043.	0.8	136
85	Persistent sensitisation to the locomotor activating effects of MDMA following MDMA self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 132, 103-107.	1.3	9
86	Pharmacological profile of novel psychoactive benzofurans. <i>British Journal of Pharmacology</i> , 2015, 172, 3412-3425.	2.7	91
87	Intravenous self-administration of mephedrone, methylone and MDMA in female rats. <i>Neuropharmacology</i> , 2015, 92, 90-97.	2.0	81
88	4,4-dimethyl-2,5-dimethylamino-1-phenylethanol (DMAR): Chemistry, Pharmacology and Toxicology of a New Synthetic Stimulant of Abuse. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 26-30.	1.2	6
89	Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. <i>Drug and Alcohol Dependence</i> , 2015, 157, 18-27.	1.6	42
90	Role of 5-HT _{2C} receptors in effects of monoamine releasers on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2015, 232, 3249-3258.	1.5	9
91	Intravenous self-administration of entactogen-class stimulants in male rats. <i>Neuropharmacology</i> , 2015, 99, 538-545.	2.0	56
92	New Psychoactive Substances. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 4-11.	1.0	56
93	Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 145-164.	0.8	30
94	The Effects of 4-Methylethcathinone on Conditioned Place Preference, Locomotor Sensitization, and Anxiety-Like Behavior: A Comparison with Methamphetamine. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv120.	1.0	28
95	Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 119-131.	0.8	35

#	ARTICLE	IF	CITATIONS
96	Reinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 133-143.	0.8	26
98	Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 49-72.	0.8	21
99	4-Fluoroamphetamine in Serum and Urine from an Intoxicated Patient with Life-Threatening Hyperpyrexia: TableÂ.. <i>Journal of Analytical Toxicology</i> , 2016, 40, 171-172.	1.7	11
100	Repeated administration of the 5-HT1B/1A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT1A and 5-HT1B receptor mechanisms. <i>Psychopharmacology</i> , 2016, 233, 1339-1347.	1.5	8
101	Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. <i>European Neuropsychopharmacology</i> , 2016, 26, 288-297.	0.3	20
102	The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. <i>Neuropharmacology</i> , 2016, 101, 68-75.	2.0	20
103	Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys. <i>Addiction Biology</i> , 2017, 22, 1169-1178.	1.4	29
104	Separation of ortho, meta and para isomers of methylmethcathinone (MMC) and methylethcathinone (MEC) using LC-ESI-MS/MS: Application to forensic serum samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1051, 118-125.	1.2	21
105	Repeated MDMA administration increases MDMA-produced locomotor activity and facilitates the acquisition of MDMA self-administration: role of dopamine D2 receptor mechanisms.. <i>Psychopharmacology</i> , 2017, 234, 1155-1164.	1.5	14
106	Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine. <i>British Journal of Pharmacology</i> , 2017, 174, 2716-2738.	2.7	28
107	N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability. <i>Neuropsychopharmacology</i> , 2017, 42, 1950-1961.	2.8	26
108	Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In Self-Administering Rats. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2648-2654.	1.7	17
109	Cocaine-like discriminative stimulus effects of α -norepinephrine-preferring monoamine releasers: time course and interaction studies in rhesus monkeys. <i>Psychopharmacology</i> , 2017, 234, 3455-3465.	1.5	8
110	Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine. <i>Drug and Alcohol Dependence</i> , 2017, 180, 39-45.	1.6	18
111	Non-medical and illicit use of psychoactive drugs. <i>Current Topics in Behavioral Neurosciences</i> , 2017, , .	0.8	2
112	The serotonin 5-HT _{2C} receptor and the non-addictive nature of classic hallucinogens. <i>Journal of Psychopharmacology</i> , 2017, 31, 127-143.	2.0	43
113	Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 33-47.	1.3	110
114	Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 152, 52-60.	1.3	13

#	ARTICLE	IF	CITATIONS
115	An Update on the Role of Serotonin and its Interplay with Dopamine for Reward. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 484.	1.0	102
116	Monoamine Transporter and Receptor Interaction Profiles of Synthetic Cathinones. <i>Current Topics in Neurotoxicity</i> , 2018, , 97-115.	0.4	4
117	Synthetic Cathinones. <i>Current Topics in Neurotoxicity</i> , 2018, , .	0.4	4
118	Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 143-164.	0.9	37
119	“Ecstasy” to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA. <i>Neuropharmacology</i> , 2018, 133, 171-180.	2.0	31
120	Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypropylamphetamine (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats. <i>Neuropsychopharmacology</i> , 2018, 43, 1753-1762.	2.8	15
121	Effects of <i>N</i> -Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1829-1839.	1.7	10
122	Pharmacological profile of mephedrone analogs and related new psychoactive substances. <i>Neuropharmacology</i> , 2018, 134, 4-12.	2.0	81
123	Reinforcing Effects of Binary Mixtures of Common Bath Salt Constituents: Studies with 3,4-Methylenedioxypropylamphetamine (MDPV), 3,4-Methylenedioxymethcathinone (methylocathinone), and Caffeine in Rats. <i>Neuropsychopharmacology</i> , 2018, 43, 761-769.	2.8	37
124	Neuropharmacology of Synthetic Cathinones. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 113-142.	0.9	61
125	New psychoactive substances – Synthetic stimulants. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 2019, 1, .	1.2	12
126	Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats. <i>Psychopharmacology</i> , 2018, 235, 3233-3241.	1.5	4
127	The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. <i>Neuropsychopharmacology</i> , 2018, 43, 2399-2407.	2.8	64
128	The Prevention and Treatment of Adolescent Stimulant and Methamphetamine Use. <i>Issues in Children's and Families' Lives</i> , 2018, , 233-260.	0.2	0
130	Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 926-931.	1.0	63
131	Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. <i>Psychopharmacology</i> , 2018, 235, 2349-2356.	1.5	8
132	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. <i>Frontiers in Pharmacology</i> , 2018, 9, 713.	1.6	14
133	Systematic Investigation into the Differences in the (+) APPI Efficiencies of Positional (Ortho, Meta,) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	2

#	ARTICLE	IF	CITATIONS
134	Medications development for food-based and drug use disorders. <i>Advances in Pharmacology</i> , 2019, 86, 197-236.	1.2	1
135	Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones. <i>Frontiers in Pharmacology</i> , 2019, 10, 438.	1.6	24
136	The synthetic cathinone psychostimulant Î±-PPP antagonizes serotonin 5-HT _{2A} receptors: In vitro and in vivo evidence. <i>Drug Testing and Analysis</i> , 2019, 11, 990-998.	1.6	8
137	The SERT Met172 Mouse: An Engineered Model To Elucidate the Contributions of Serotonin Signaling to Cocaine Action. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3053-3060.	1.7	8
138	2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and Î±2-adrenergic receptors. <i>Psychopharmacology</i> , 2019, 236, 989-999.	1.5	3
139	Pharmacological characterization of the aminorex analogs 4-MAR, 4,4-DMAR, and 3,4-DMAR. <i>NeuroToxicology</i> , 2019, 72, 95-100.	1.4	11
140	Effects of cocaine on the discriminative stimulus and reinforcing effects of mephedrone in male rats. <i>Psychopharmacology</i> , 2019, 236, 1043-1056.	1.5	2
141	The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. <i>Psychopharmacology</i> , 2019, 236, 915-924.	1.5	12
142	Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. <i>Psychopharmacology</i> , 2019, 236, 939-952.	1.5	42
143	Behavioral economic analysis of the reinforcing effects of ðœbath saltsðœ-mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats. <i>Psychopharmacology</i> , 2019, 236, 1031-1041.	1.5	16
144	The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. <i>Drug Delivery and Translational Research</i> , 2020, 10, 271-281.	3.0	3
145	The potent psychomotor, rewarding and reinforcing properties of 3-fluoromethamphetamine in rodents. <i>Addiction Biology</i> , 2020, 25, e12846.	1.4	7
146	Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters. <i>Frontiers in Pharmacology</i> , 2020, 11, 673.	1.6	13
147	Transdermal Delivery of the Free Base of 3-Fluoroamphetamine: In Vitro Skin Permeation and Irritation Potential. <i>AAPS PharmSciTech</i> , 2020, 21, 109.	1.5	3
148	Construction of pioneering quantitative structure activity relationship screening models for abuse potential of designer drugs using index of ideality of correlation in monte carlo optimization. <i>Archives of Toxicology</i> , 2020, 94, 3069-3086.	1.9	22
149	The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in rats. <i>Behavioural Pharmacology</i> , 2020, 31, 309-321.	0.8	3
150	Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats. <i>Psychopharmacology</i> , 2020, 237, 1681-1689.	1.5	3
151	Designer drugs: mechanism of action and adverse effects. <i>Archives of Toxicology</i> , 2020, 94, 1085-1133.	1.9	138

#	ARTICLE	IF	CITATIONS
152	Convenient ultrasonic preparation of a water stable cluster-based Cadmium(II) coordination material and highly sensitive fluorescent sensing for biomarkers DPA and 5-HT. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 247, 119092.	2.0	7
153	Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. <i>Journal of Psychopharmacology</i> , 2021, 35, 512-536.	2.0	22
154	Drugs of Abuse Affecting 5-HT _{2B} Receptors. <i>Receptors</i> , 2021, , 277-289.	0.2	3
155	The Reward System and Post-Traumatic Stress Disorder: Does Trauma Affect the Way We Interact With Positive Stimuli?. <i>Chronic Stress</i> , 2021, 5, 247054702199600.	1.7	30
156	Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 202, 173112.	1.3	13
157	Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. <i>Journal of Neurochemistry</i> , 2021, 157, 1714-1724.	2.1	18
158	Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity in vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 654061.	1.6	9
159	Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 656-665.	1.0	3
160	Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. <i>Life</i> , 2021, 11, 440.	1.1	11
161	Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca ²⁺ channels as sensors. <i>Toxicology and Applied Pharmacology</i> , 2021, 419, 115513.	1.3	6
162	±-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter. <i>Neuropharmacology</i> , 2021, 190, 108570.	2.0	15
163	Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. <i>Experimental Neurology</i> , 2021, 343, 113778.	2.0	30
164	Pharmacological profiling of novel psychoactive substances. , 2022, , 109-130.		0
165	Synthetic amphetamine derivatives, benzofurans, and benzodifurans. , 2022, , 247-278.		1
166	Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions. , 2008, , 311.		3
167	Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. <i>Psychopharmacology</i> , 2020, 237, 1471-1480.	1.5	34
168	Methaemoglobinaemia due to mephedrone ('snow'). <i>BMJ Case Reports</i> , 2010, 2010, bcr0420102879-bcr0420102879.	0.2	11
169	The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts". <i>Journal of Addiction Research & Therapy</i> , 2013, 04, .	0.2	52

#	ARTICLE	IF	CITATIONS
170	Profile of MDMA Self-Administration from a Large Cohort of Rats: MDMA Develops a Profile of Dependence with Extended Testing. <i>Journal of Drug and Alcohol Research</i> , 2012, 1, 1-6.	0.9	19
171	(2-Aminopropyl)benzo[¹²]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. <i>Neuropsychopharmacology</i> , 2022, 47, 914-923.	2.8	8
173	The role of extracellular serotonin and MDMA in the sensitizing effects of MDMA. <i>Behavioural Brain Research</i> , 2022, 430, 113936.	1.2	1
175	4-Fluoroamphetamine (4-F-A) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, .	0.4	0
176	Serotonin-releasing agents with reduced off-target effects. <i>Molecular Psychiatry</i> , 2023, 28, 722-732.	4.1	10
177	Persistent binding at dopamine transporters determines sustained psychostimulant effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	5
178	Rate of onset of dopamine transporter inhibitors assessed with intracranial self-stimulation and in vivo dopamine photometry in rats. <i>Psychopharmacology</i> , 2023, 240, 969-981.	1.5	1